<DOC>
	<DOCNO>NCT01369550</DOCNO>
	<brief_summary>The purpose clinical trial evaluate whether omega-3 fatty acid stearidonic acid ( SDA ) , use food ingredient , increase level long-chain omega-3 fatty acid eicosapentaenoic acid ( EPA ) red blood cell ( RBC ) membrane men woman .</brief_summary>
	<brief_title>Efficacy Study Stearidonic Acid ( SDA ) Soybean Oil-containing Foods Red Blood Cell Fatty Acid Content</brief_title>
	<detailed_description />
	<criteria>1 . Subject male female , 21 65 year age , inclusive . 2 . Body mass index ( BMI ) ≥18.00 &lt; 40.00 kg/m2 visit 1 , week 2 . 3 . Subject health condition would prevent him/her fulfil study requirement judge Investigator basis medical history routine laboratory test result . 4 . Subject willing avoid alcohol consumption 24 h prior every clinic visit . 5 . Subject plan change smoke habit study period . 6 . Subject willing maintain stable body weight , activity level dietary pattern except use study product , direct . 7 . Subject understands study procedure sign form provide informed consent participate study authorization release relevant protect health information study Investigator . 1 . Subject coronary heart disease coronary heart disease risk equivalent include follow : 1 . Diabetes mellitus ( fast glucose ≥126 mg/dL visit 1 , week 2 ) ; 2 . Clinical sign atherosclerosis include peripheral arterial disease , abdominal aortic aneurysm , carotid artery disease [ symptomatic ( e.g. , transient ischemic attack stroke carotid origin ) &gt; 50 % stenosis angiography ultrasound ] form clinical atherosclerotic disease ( e.g. , renal artery disease ) ; 3 . Presence multiple risk factor give person great 20 % chance develop coronary artery disease within 10 year . This determine Framingham risk index calculate visit 1 , week 2 . 2 . Abnormal laboratory test result clinical significance , include , limited creatinine ≥1.5 mg/dL ALT AST ≥1.5X upper limit normal visit 1 , week 2 . 3 . TG ≥400 mg/dL visit 1 , week 2 . 4 . Subject smoke one pack cigarettes ( 20 cigarette ) per day . 5 . Subject history presence clinically important renal , hepatic , pulmonary , biliary , gastrointestinal , neurologic endocrine disorder judgment Investigator , would interfere subject 's ability provide inform consent , comply study protocol ( might confound interpretation study result ) , put subject undue risk . Stable , treated hypothyroidism allow . 6 . Uncontrolled hypertension ( systolic blood pressure ≥160 mm Hg diastolic blood pressure ≥100 mm Hg define average blood pressure measure visit 1 , week 2 ) . One retest allow separate day prior visit 2 , week 0 subject whose blood pressure exceed either cut point visit 1 , week 2 . 7 . Unstable use ( initiation change dose ) within four week visit 1 ( week 2 ; Appendix 1 ) antihypertensive medication thyroid hormone replacement . 8 . Use lipidaltering drug , include statin , bile acid sequestrants , cholesterol absorption inhibitor , fibrates , prescription formulation niacin within four week visit 1 ( week 2 ) throughout study . If subject need wash drug , he/she consent ask return four week washout . 9 . Use EPA/DHA drug supplement within four month visit 1 , week 2 throughout study period . If subject use &gt; 1.0 g/d EPA , DHA , combination EPA DHA drug supplement , use must discontinue least six month prior visit 1 , week 2 blood draw . 10 . Frequent use ( twice per month ) nonstudyrelated EPA/DHA contain enrich food ( DHAenriched eggs ) within four month visit 1 , week 2 avoidance enrich food throughout study period . 11 . Use ALAcontaining seed oil ( i.e. , flaxseed , perilla seed , hemp , spirulina , walnut , mustard seed black currant oil ) one week duration within four week visit 1 , week 2 throughout study period . 12 . Consumption fatty fish ( salmon , herring , mackerel , albacore tuna , sardine ) twice per month within four month visit 1 , week 2 . Unwillingness avoid fish , except shellfish crustacean , throughout study period ( Appendix 6 . Note : recognize many fish significant source omega3 fatty acid ; however , food restrict simplify dietary advice lowdose SDA study ) . 13 . Use dietary supplement know alter lipid metabolism , include limited : dietary fiber supplement , red rice yeast supplement , garlic supplement , soy isoflavone supplement , sterol/stanol product , policosanols , niacin analogue dose &gt; 50 mg/d , others discretion Investigator within four week prior visit 1 , week 2 study . If subject need discontinue lipidaltering supplement ( ) , he/she washout four week prior screen visit procedure ( visit 1 , week 2 ) . 14 . Use weightloss medication ( prescription overthe counter ) include , limited , lipase inhibitor [ orlistat ( alli™ ) ] , within four week prior visit 1 , week 2 throughout study . 15 . Use weight loss supplement program within four week visit 1 , week 2 throughout study . 16 . Known allergy sensitivity study product ingredient study product ( study product may contain milk , soy wheat ) . 17 . Subject history presence cancer prior two year , except nonmelanoma skin cancer ( e.g. , basal squamous cell carcinoma skin ) . 18 . Females pregnant , plan pregnant study period , lactate , woman childbearing potential unwilling commit use medically approve form contraception throughout study period . The method contraception must record source documentation . 19 . Current recent history ( within 12 month visit 1 , week 2 ) strong potential alcohol substance abuse . Alcohol abuse define &gt; 14 drink per week ( 1 drink = 12 oz beer , 5 oz wine , 1 ½ oz distil spirit ) . 20 . Exposure nonregistered drug product within 30 day prior screen visit ( visit 1 , week 2 ) .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2011</verification_date>
</DOC>